VECIMA-NETWORKS
18.3.2024 12:31:26 CET | Business Wire | Press release
Vecima Networks Inc. (TSX: VCM) today announced that LICA CZECH s.r.o. (further as LICA) is deploying Vecima's Entra® SC-1D and Entra® Access Controller (EAC) solutions for Elsat, spol. s.r.o. (further as Elsat), a provider of telecommunications services in the Czech Republic.
The deployment for Elsat gives LICA a launching point as it introduces Vecima's technology to the Czech Republic in the form of an innovative Remote MACPHY Device (RMD) Distributed Access Architecture (DAA) application.
Vecima's SC-1D, a cornerstone of the Entra family, is specifically designed for DAA applications, enabling operators like Elsat to transition their networks toward a more distributed, efficient, and scalable architecture. The SC-1D simplifies network design and enhances operational efficiency by moving PHY layer functions closer to the network edge, thereby reducing latency and increasing bandwidth availability.
Complementing the SC-1D, Vecima's Entra Access Controller (EAC) serves as a centralized management platform that orchestrates the complex interactions between the core network and distributed access devices. The EAC ensures seamless integration and optimal performance of the DAA ecosystem, facilitating advanced features such as dynamic bandwidth allocation and network virtualization.
“LICA is proud to partner with Vecima to bring its industry-leading DAA solutions to operators in the Czech Republic,” said Peter Link, CEO at LICA. “Vecima is known for its reliability and innovation, the very foundation of LICA’s mission. Our partnership can help change the landscape of broadband innovation in the Czech Republic.”
Elsat's adoption of Vecima's DAA follows comprehensive field trials and lab staging. The deployment is expected to significantly bolster Elsat's capability to deliver high-quality, reliable services to its customers, thereby reinforcing its position as a technology leader in the Czech telecommunications sector.
“With the DAA solution from LICA and Vecima, Elsat is evolving our broadband network to the next generation, providing our subscribers with faster speeds and higher reliability,” said Petr Bárta, CEO at Elsat. “We are optimizing our existing infrastructure and building a strong future for our company.”
Ryan Nicometo, Senior Vice President and General Manager, Vecima Video & Broadband Solutions, added, “This deployment showcases the flexibility and power of Vecima's DAA solutions, designed to meet the evolving needs of modern networks and enhance the end-user experience.”
The strategic partnership underscores Vecima's commitment to innovation and its role in driving the global evolution of content-rich, multi-gigabit networks through its advanced solutions. For more information about Vecima’s Entra DAA platform, visit vecima.com/network-access/interoperable-daa-solutions.
About LICA CZECH s.r.o.
LICA specializes in delivering innovative network solutions and services. By partnering with leading technology providers, LICA offers comprehensive solutions tailored to meet the diverse needs of its clientele. Learn more at www.lica.cz.
About Elsat, spol. s.r.o.
Elsat, based in České Budějovice, Czech Republic, is a multisystem provider of telecommunications services. Dedicated to delivering cutting-edge solutions, Elsat offers a broad spectrum of services to both residential and commercial customers. Learn more at www.elsat.cz.
About Vecima Networks
Vecima Networks Inc. (TSX: VCM) is leading the global evolution to the multi-gigabit, content-rich networks of the future. Our talented people deliver future-ready software, services, and integrated platforms that power broadband and video streaming networks, monitor and manage transportation, and transform experiences in homes, businesses, and everywhere people connect. We help our customers evolve their networks with cloud-based solutions that deliver ground-breaking speed, superior video quality, and exciting new services to their subscribers. There is power in connectivity – it enables people, businesses, and communities to grow and thrive. Learn more at www.vecima.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240318517114/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom